Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree that this seems to be a wash and repeat of the previous several years. It sucks that the company(s) keep doing this.
I still cant believe they Paid Ridgeway Therapeutics, Inc. to get their Patents back.
"We issued all 8,000 shares of the Series F stock to Ridgeway Therapeutics, Inc. in connection with the Termination Agreement "
Should have been a breach of contract for not making their payments to Inspyr for the use of the Patents.
There is something there with this drug Mipsagargin.
These researchers are real:
John T Isaacs
BrennenSøren Brøgger Christensen
Samuel R Denmeade
The Company(s) trying to capitalize on this drug are just F-ing idiots.
Havent posted here in a long time.
I continue to get Research updates related to Mipsagargin.
https://www.researchgate.net/publication/356925137_Mipsagargin_The_Beginning-Not_the_End-of_Thapsigargin_Prodrug-Based_Cancer_Therapeutics
https://www.mdpi.com/1420-3049/26/24/7469
Published December 9th, 2021
"Do you all think it's retail that just happened to have $120-$130,000K lying around"
I've been noticing this also with those multiple blocks of 4k+ shares at a time during the day, sitting there being nibbled by retail investors 100 or 300 at a time, and then BOOM.... The remaining shares just get eaten up all at once. Shorts covering big time, supply and demand, price increasing... $GMGI is making so much noise right now swing traders are going to be having a field day and we are going to see continued $1+ swings throughout the day.
Strength of long-term holders who have been accumulating over the last 1+ years!! This isnt even close to the REAL PAYDAY coming upon Uplist!!!
"Obviously," said Golden Matrix CEO Brian Goodman, "we are thrilled by this opportunity to enter the burgeoning sports betting market with a superior product offering. This state-of-the-art sports platform has already obtained a gaming license in multiple states in the USA.[color=red][/color]
https://www.marketwatch.com/press-release/golden-matrix-receives-license-to-market-and-distribute-white-label-sportsbook-for-online-betting-2020-10-28-91842534?mod=mw_quote_news_seemore
US Patent - 15/100,780 PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE. Original denial of Patent was reversed on 7/29/2020, Patent Fees have been paid and Patent was "Dispatched to FDC" (Final Data Capture Stage)
FDC sent on 10/9/2020
Read for yourself in screenshot below
Patent will be granted within the next 5 weeks
Trying to find the continued let down DPS1212 is talking about.
Looking at the 6 month chart shows a VERY healthy growth uptrend.
Guess his let down means the HEALTHY dips where the stock just keeps going back up!
You better believe i will be buying on those "let downs" or dips he is so kindly pointing out for all of us!
The ask is getting ANNIHILATE
AND the milly bids keep coming back in taking this higher
$GMGI
its gone now lol
They are awake lol
Less than an hour and already past yesterdays total volume!!
Lots of new eyes!!
$GMGI Strong!!
Less than an hour and already past yesterdays total volume!!
Lots of new eyes!!
$GMGI Strong!!
Britt just requested to Join that group!
Thanks for creating!
Will Hummel
I questioned a Brazilian researcher last year on his research paper and got some good feed back regarding Mipsargin.
It is definitely something many are studying.
From: Antonio Claudio Tedesco <atedesco@usp.br>
Sent: Sunday, May 26, 2019 11:19 AM
To: William Hummel <William.Hummel@XXX.edu>; atedesco <atedesco@usp.br>
Subject: Re: Expert Review of Anticancer Therapy - Prodrugs for targeted cancer therapy
Dear Dr William Hummel.
Thank you for the additional information. We could see progress with Mipsagargin, what seen very good.
I agree with you, scaling up clinical trial to phase III need for sure good and affordable production of the compounds. We face the same problem in the University and selects partners that acquire the rights to transfer the technology in other project.
But the studies are already in phase III put the INSPYR product in different situation than other. I am glad to listen and for sure and be glad to update new in my future talks.
Thank you very much for the attention
Best Regards
Prof.Dr. Antonio Claudio Tedesco
Center of Nanotechnology and Tissue Engineering
Photobiology and Photomedicine research Group FFCLRP- São Paulo University
Ribeirão Preto, SP, Brazil Av. Bandeirantes, 3900 – Monte Alegre – Ribeirão Preto – SP – CEP 14040-901.
Campus USP – Rua Prof. Aymar Baptista Prado, Depto de Química. Bloco 17
FAX 016-33154838 Tel 016-33153751
sites.ffclrp.usp.br/nanotecnologiafomed
On Fri, May 10, 2019 at 9:10 AM William Hummel <William.Hummel@XXX.edu> wrote:
Professor Tedesco
I purchased this article “Prodrugs for targeted cancer therapy” from Taylor & Francis the other day.
I purchased it because I am a part time investor that has been researching a company “Inspry Therapeutics” that owns the Patents for Mipsagargin/G-202.
You mentioned Phase II trials for Mipsagargin in this article with a reference [63] that I can’t tie to Mipsagargin or the Trials.
“However, after promising phase I test results, the phase II trials were
unsuccessful and no new tests were subsequently carried out, indicating that the clinical development
of this prodrug has stopped [63] .”
“Reference 63. - Huang S-X, Yun B-S, Ma M, et al. Leinamycin E1 acting as an anticancer prodrug activated by
reactive oxygen species. Proceedings of the National Academy of Sciences. 2015;112(27):8278.”
In the attached Corporate Presentation dated 10/12/2016 PDF it shows the success of Phase II Trials and the promising outlook for Mipsagargin.
It was the last Corporate Presentation put out by the company.
In this next article it shows the need for synthetic Thapsigargin due to its natural production not currently feasible for the amount needed for Phase III. https://cen.acs.org/articles/95/i19/Improved-routes-thapsigargin.html
I do have more articles showing progress that has been made with the most recent article published in Dec 2018.
Dec 2018 - Conclusions: Shoot regeneration, rooting and biomass growth from leaf explants of T. garganica were achieved, together with a high yield in vitro production of thapsigargin in TIBs.
https://www.researchgate.net/publication/327536730_Use_of_a_temporary_immersion_bioreactor_system_for_the_sustainable_production_of_thapsigargin_in_shoot_cultures_of_Thapsia_garganica
My belief is that the company cannot proceed with a Phase III Trial until the supply issue has been resolved.
William Hummel
Two treatment regimens were evaluated during the safety run-in phase: mipsagargin at 40 mg/m2 on Days 1, 2, and 3 (Dose Level -1) and mipsagargin at 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3 (Dose Level 1).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
section 2.3 under Treatment
correct 1 metric ton = 10,000,000
10 million milligrams
1. European Patent GRANTED 4/9/2020
2. Phase II Clinical Trial NCT01777594 -
Published article June 17, 2019
Published article - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
3. 500k funding deal (8k July 3rd, 2018) was to be used for SEC filings when the time arose. They got current, 2 years behind, with the SEC during the summer of 2019. No reason to spend $250k if nothing in the works. Someone invested that in 2018 knowing something was coming down the Pipeline.
4. Timing of both 2 and 3.
5. The biggest holdup WAS moving forward with synthesizing the drug Thapsigargin.
A. PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE
B. https://portal.uspto.gov/pair/PublicPair Search Application Number 15/100780
C. European Letter of intent to Grant Patent 11/21/2019
D. European Patent payment paid 3/27/2020
E. European Patent GRANTED 4/9/2020, will be published in European Patent Bulletin on 6/5/2020
F. https://globaldossier.uspto.gov/#/result/application/US/15100780/330564
G. https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=E0649B8F2FF0A43119C9DAE4E3D9B95D.wapp1nB?docId=EP178299671&tab=NATCOLLDOCUMENTS
6. Number 5 is/WAS so important because of the cost of current supply of Mispagargin - read my ihub post # 9850 dated 2/21/2020. No company can put this upfront cost in ONLY the Drug aspect of a Clinical trial. Again this is only the cost of the DRUG itself for Phase III Clinical Trial. No wonder they aren’t spending money, communicating, advertising.
Links, vendor email and more information are in my previous post #9850 but here is the meat:
100 mg sized unit of Mipsagargin cost $4850
Phase III needs a metric ton a year.
10 million bottles at 100 mg each x $4850 = $48.5 billon
7. Back to #5/B. - U.S. Patent review 7/29/2019 - did not go as expected. Phyton BioTech's requested an Oral Hearing with a scathing letter to the U.S. Patents office on 9/30/2019. U.S. Patent office acknowledge letter and assigned appeal on 10/1/2019.
Currently still waiting for U.S. Patent Office to actually schedule the appeal Date.
Updated info coming at noon... just need to finish writing it up
Macau Casinos down 88% for the month of February. Gamblers aren’t traveling.
Where are they getting their fix?
I’m betting one of those beneficiaries is gonna be GMGI
Twitter and their website blog are blowing up in the last hour
http://inspyrtherapeutics.com
Is this their new website?
Something to think about regarding the value of Mipsagargin and the need for Phyton Biotech to be granted the Patent to synthesize Thapsigargin.
https://cen.acs.org/articles/95/i19/Improved-routes-thapsigargin.html
Dated May, 2017
Inspyr Therapeutics is believed to be close to starting Phase III human trials of mipsagargin. For future trials, companies may need a metric ton per year of thapsigargin, Christensen says
100 mg sized unit is $4850
Phase III needs a metric ton a year.
10 million bottles at 100 mg each x $4850 = $48.5 billon
No wonder Inspyr or anyone else can't to go to Phase III at this point.
No Pharma company could absorb that kinda investment..
Email thread with a supplier today:
-----Original Message-----
From: glixx@glixxlabs.com <glixx@glixxlabs.com>
Sent: Friday, February 21, 2020 12:28 PM
To: William <XXX@jefferson.edu>
Subject: RE: GLXC-12700 (Mipsagargin)
The minimum 100 mg sized unit is $4850, delivery in 15 weeks
-----Original Message-----
From: William <XXX@jefferson.edu>
Sent: Friday, February 21, 2020 12:23 PM
To: glixx@glixxlabs.com
Subject: RE: GLXC-12700 (Mipsagargin)
Chris
I am looking for pricing at this time.
Can you provide your price structure?
What does quantity of 1 equate to?
What is the cost of quantity of 1 vs 10 vs 100?
Thank You
-----Original Message-----
From: glixx@glixxlabs.com <glixx@glixxlabs.com>
Sent: Friday, February 21, 2020 11:24 AM
To: William <XXX@jefferson.edu>
Subject: GLXC-12700 (Mipsagargin)
Hi, William:
Please let us know the quantity that you may need for GLXC-12700 (Mipsagargin) so as we can quote you back, Thank you very much!
Chris Budadonn
Customer Supporting
Glixx Laboratories
ErieViewer148 - Regarding your comment "Research reports are irrelevant"
In all of the SEC 10k and 10Q filings since they curtailed operations in February 2018:
We are dependent upon third parties to develop our product candidates, and such parties are, to some extent, outside of our control.
We depend upon independent contract research organizations, investigators and collaborators, such as universities and medical institutions, to conduct our pre-clinical and clinical studies.
Both Reverse splits were minimal. Most recent split was 1/25 compared to what they could have down 1/500.
A company sells shares to raise money.
Until they release updated Share information its hard to make any assumptions about who is getting paid. They only have 1 employee, Mr. Cain, who's employment will not receive any compensation at this time per SEC filings and no overhead costs.
Market Manipulators and day traders are the ones making quick minimal profits unfortunately.
They got rid of Chris Lowe and FLG who did nothing for the company but change its name, got mixed up with Milost Global scam and authorized 2 Reverse Splits. Mr. Lowe's first and only Investor presentation Oct. 2016 was a copy of Craig Dionne's presentation from Sept. 2015. Only significant change was the company name and logo from Genspera to Inspyr Therapeutics.
I do agree the amount you and I lost sucks.
I've learned some things from this stock play.
I hope you have also.
I believe in the independent research that I hope will one day transform this stock.
Until than Good Luck Investing.
From the Journal of Natural Product Reports
Peer Reviewed, Published Research Dated 2/18/2020
https://pubs.rsc.org/en/content/articlelanding/2020/np/c9np00066f#!divAbstract
After extracellular cleavage, the released hydrophobic thapsigargin can enter the cancer cells and promote Ca2+-mediated cell death. Importantly, the prodrug mipsagargin (Fig. 8), is inactive against SERCA, which helps to minimize off-target cellular cytotoxicity. Mipsagargin is currently investigated in late stage clinical trials against prostate cancer, progressive glioblastoma and hepatocellular carcinoma
Update on Clinical Trial NCT01777594 - June 17, 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
"These findings warrant a larger clinical study to further characterize the activity of mipsagargin in advanced HCC".
Drug lesson..
Continued Scientific Peer Reviewed Research.
I post those websites frequently on this board.
Drugs aren't made overnight.
Mipsagargin is not made naturally in a commercially viable supply stream.
https://globaldossier.uspto.gov/#/result/application/US/15100780/289860
European Patent Office:
Communication of intention to grant European Patent 11/21/2019
Application No: 14 835 563.9 - 1111
Ref. W3228 EP
Applicant Phyton Holdings, LLC
U.S. Patent Office
https://portal.uspto.gov/pair/PublicPair
Application Number: 15/100780
PRODUCTION OF THAPSIGARGINS BY THAPSIA CELL SUSPENSION CULTURE
https://www.marketwatch.com/press-release/phyton-biotech-achieves-manufacturing-milestone-with-thapsigargin-the-active-agent-in-mipsagargin-2016-08-22
Phyton BioTech - Phyton’s Plant Cell Fermentation (PCF®) development program that now has begun to define the process by which the Thapsia plant is converted into a preserved, fermentable cell line, thus providing a more sustainable source of high-quality thapsigargin.
Clear DD for continued scientific research:
https://www.researchsquare.com/article/f73e8460-86c9-43e4-930a-838aae7e8d16/v2
Currently Article Status - Under Review
Version 2 Posted January 29th, 2020
Background section of article:
Currently, Thapsigargin become a research hotspot of the anticancer drug Mipsagargin,[color=red][/color] and it is TenctlyThapsia garganica CYP76AE2 that mediates the conversion of epikunzeaol to epidihydrocostunolide compounds which are possible intermediates in thapsigargin biosynthesis [6
https://www.sciencedirect.com/science/article/pii/S0753332220301451
Release Date - May 2020
SLs have received considerable attention due to their potent bioactivities, including cancer cell cytotoxicity and antineoplastic efficacy in vivo studies, such as artemisinin [3], parthenolide [4], and thapsigargin [5], which are emerging as promising anticancer leads or prodrugs [8].[color=red][/color]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986015/
January 27th, 2020 - One Prodrug - Mipsagargin (G202)
Moreover, one prodrug has reached the stage of clinical phase II trials, where it recently was demonstrated to promote prolonged disease stabilization in patients with advanced hepatocellular carcinoma [59].
Anyone know who M. J. Borad is?
He has been linking Inspyr Therapeutics to a lot of his research.
It’s was is in the financials that Universities are studying their patents!!
I’ll post links tomorrow
Went in for a back injection for pain at 2:30pm, come out to this.... I think I’m gonna ask for another injection before 4pm to keep this rally going ??
Research member of Inspyr Therapeutics, Søren Brøgger Christensen.
Still investigating and publishing 1/27/2020 information on Thapsigargin and Prodrug Mipsagargin and its ability to Stabilize cancer patients.
https://biosignaling.biomedcentral.com/articles/10.1186/s12964-019-0499-z
"Moreover, one prodrug has reached the stage of clinical phase II trials, where it recently was demonstrated to promote prolonged disease stabilization in patients with advanced hepatocellular carcinoma [59]"
Agreed, they curtailed.
No pumping PR's of this stock.
No wasting of money.
They continue to stay current with the SEC I believe since Phyton BioTech is on the cusp of being Granted Patent's for synthesizing Thapsigargin, 5+ years in the making..
European Patent Office has already communicated its intention to Grant the Patent 11/21/2019
https://globaldossier.uspto.gov/#/result/application/US/15100780/93114
Mipsagargin is still being studied and published by numerous Universities and Scientific Communities.
I'm betting on this stock purely from a Scientific Research view point.
A little continued background study of NSPX's leading drug Mipsagargin: Update 1/21/2020[color=red][/color]
Science of drugs doesnt happen overnight
Everyone should Know what they own here!
January 21, 2020[color=red][/color]
https://link.springer.com/article/10.1007/s12015-019-09942-y
Conventional chemo-radiotherapies are not effective against quiescent, slowly (or non-) dividing CSCs, thereby become resistant and subsequently repopulate the tumour [112]. Interestingly, it was found that a compound named thapsigargin targets highly plastic CSCs in a proliferation independent fashion and can thus effectively target quiescent cells [113, 114]. However, thapsigargin is not selective for cancer cells, but recent efforts to modify it as a tumour-targeted pro-drug have greatly improved the specificity profile and undergoing phase II trials (NCT01056029) [115].
Update on Clinical Trial NCT01056029 - April 26th, 2016[color=red][/color]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984914/
Update on Clinical Trial NCT01777594 - June 17, 2019[color=red][/color]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
Conclusions:
In conclusion, mipsagargin is a first-in-class PSMA-targeted prodrug that may be an effective therapeutic strategy in patients with HCC, a disease characterized as highly vascularized. Infusion of 40 mg/m2 mipsagargin over a 1-hour period on Days 1, 2 and 3 of 28-day cycles was relatively well tolerated and resulted in disease stabilization, decreased tumor blood flow as observed by decrease Ktrans, and prolonged TTP in a population of patients who had progressed on prior treatment with sorafenib. These observations importantly suggest that mipsagargin may have clinical activity in HCC, including in the population of patients with advanced, refractory HCC. In this study, exploratory analyses suggested that mipsagargin decreased blood flow in HCC lesions and in metastatic sites relative to baseline examination within two cycles of exposure to mipsagargin. These findings warrant a larger clinical study to further characterize the activity of mipsagargin in advanced HCC.
I’ll sticky it tomorrow morning.
Waiting on Phyton BioTech to Patent their Production of Thapsigargin.
European Patent Office has already Communicated their Intention to GRANT Phyton Biotech a Patent on 11/21/2019
https://globaldossier.uspto.gov/#/result/application/US/15100780/926004
Gonzo: A little continued background study of NSPX's leading drug Mipsagargin: Update 1/21/2020[color=red][/color]
Science of drugs doesnt happen overnight
Everyone should Know what they own here!
January 21, 2020[color=red][/color]
https://link.springer.com/article/10.1007/s12015-019-09942-y
Conventional chemo-radiotherapies are not effective against quiescent, slowly (or non-) dividing CSCs, thereby become resistant and subsequently repopulate the tumour [112]. Interestingly, it was found that a compound named thapsigargin targets highly plastic CSCs in a proliferation independent fashion and can thus effectively target quiescent cells [113, 114]. However, thapsigargin is not selective for cancer cells, but recent efforts to modify it as a tumour-targeted pro-drug have greatly improved the specificity profile and undergoing phase II trials (NCT01056029) [115].
Update on Clinical Trial NCT01056029 - April 26th, 2016[color=red][/color]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984914/
Update on Clinical Trial NCT01777594 - June 17, 2019[color=red][/color]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
Conclusions:
In conclusion, mipsagargin is a first-in-class PSMA-targeted prodrug that may be an effective therapeutic strategy in patients with HCC, a disease characterized as highly vascularized. Infusion of 40 mg/m2 mipsagargin over a 1-hour period on Days 1, 2 and 3 of 28-day cycles was relatively well tolerated and resulted in disease stabilization, decreased tumor blood flow as observed by decrease Ktrans, and prolonged TTP in a population of patients who had progressed on prior treatment with sorafenib. These observations importantly suggest that mipsagargin may have clinical activity in HCC, including in the population of patients with advanced, refractory HCC. In this study, exploratory analyses suggested that mipsagargin decreased blood flow in HCC lesions and in metastatic sites relative to baseline examination within two cycles of exposure to mipsagargin. These findings warrant a larger clinical study to further characterize the activity of mipsagargin in advanced HCC.
What’s your basis for your comment. I Own shares and have been following this stock for a while now.
Sabby filing SC 13G/A - Targeting NSPX, 4 different funds at 9.99% ownership each.
Item 4.
Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item
1.
(a)
Amount beneficially owned:
Sabby Healthcare Master Fund, Ltd. - 1,137,260
Sabby Volatility Warrant Master Fund, Ltd. - 1,137,260
Sabby Management, LLC - 1,137,260
Hal Mintz - 1,137,260
(b)
Percent of class:
Sabby Healthcare Master Fund, Ltd. - 9.99%
Sabby Volatility Warrant Master Fund, Ltd. - 9.99%
Sabby Management, LLC - 9.99%
Hal Mintz - 9.99%
Sabby Healthcare Master Fund, Ltd.
By: /s/ Harry Thompson
Name: Harry Thompson
Title: Authorized Person of TDF Management Ltd.,
a Director
Sabby Volatility Warrant Master Fund, Ltd.
By: /s/ Harry Thompson
Name: Harry Thompson
Title: Authorized Person of TDF Management Ltd.,
a Director
Sabby Management, LLC*
By: /s/ Robert Grundstein
Name: Robert Grundstein
Title: Chief Operating Officer
/s/ Hal Mintz*
Hal Mintz
Not yet.